Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 study of PV-10 for metastatic melanoma will be presented at the HemOnc Today - Melanoma and Cutaneous Malignancies Conference on April 13, 2012.
More...